Ruxolitinib ≥98% (by HPLC)
Supplier: ADIPOGEN CORP MS
|
Warning
|
Synonyms:
(R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile, INCB018424, Ruxolitinib
Antineoplastic, anti-inflammatory and immunomodulating agent. Orally bioavailable potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5nM, respectively and is less selective for JAK3 (IC50=322nM). Affects DC differentiation and function, leading to impaired T cell activation. Used in the treatment of myeloproliferative neoplasms and psoriasis. Anticancer agent. Shown to induce apoptosis and autophagy. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro.
Formula:
C₁₇H₁₈N₆ MW: 306.4 g/mol Storage Temperature: Freezer |
MDL Number:
MFCD12031592 CAS Number: 941678-49-5 |
Specification Test Results
Purity | >98% (HPLC) |
Appearance/Color | White to off-white solid. |
Solubility | Soluble in DMSO or ethanol. Insoluble in water. |
Learn more
About VWR
Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...